<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00361153</url>
  </required_header>
  <id_info>
    <org_study_id>WEL-202</org_study_id>
    <nct_id>NCT00361153</nct_id>
  </id_info>
  <brief_title>Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to test whether WelChol (colesevelam HC1) improves blood sugar control&#xD;
      in patients with type 2 diabetes by making their own insulin work more efficiently.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single-center, randomized, parallel, double-blind, placebo controlled, 8-week trial in&#xD;
      subjects with type 2 diabetes mellitus. Two parallel treatment groups include double-blind&#xD;
      colesevelam or placebo. A screening period may be up to 18 weeks to withdraw non sulfonylurea&#xD;
      antidiabetic treatment or withdraw or adjust sulfonylurea antidiabetic treatment. To evaluate&#xD;
      hepatic and peripheral insulin sensitivity, subjects will undergo a two-step&#xD;
      hyperinsulinemic-euglycemic clamp with a tritiated glucose infusion at pre randomization and&#xD;
      after 8 weeks of treatment. To evaluate oral glucose absorption, subjects will undergo two&#xD;
      oral glucose tolerance tests (OGTT) at pre randomization, one without colesevelam and one&#xD;
      with colesevelam, and one OGTT at the end of the treatment period..&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effect of 8 weeks treatment with WelChol on insulin sensitivity,as measured by the hyperinsulinemic-euglycemic clamp method, i.e., placebo-corrected change from baseline in M-value.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of 2 weeks treatment with WelChol on insulin sensitivity,as measured by the hyperinsulinemic-euglycemic clamp method.</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate acute and chronic effects of treatment with WelChol on plasma glucose after ingestion of a standard meal replacement.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of treatment with WelChol on HbA1C, insulin, fasting plasma glucose, and fructosamine.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Colesevelam hydrochloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colesevelam hydrochloride</intervention_name>
    <description>Welchol tablet 625mg</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Welchol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects meeting the following criteria at the Screening Visit will be eligible to&#xD;
        participate in the trial:&#xD;
&#xD;
          -  Have given written informed consent&#xD;
&#xD;
          -  Ages 18 to 75 years, inclusive&#xD;
&#xD;
          -  Diagnosis of type 2 diabetes mellitus of at least 3 months duration&#xD;
&#xD;
          -  HbA1C 7.0- 10.0%, inclusive&#xD;
&#xD;
          -  Antidiabetic treatment may include oral agents; all antidiabetic agents must be&#xD;
             withdrawn before randomization&#xD;
&#xD;
          -  Women may be enrolled if they are not pregnant (negative serum βHCG at the Screening&#xD;
             Visit), are not breast-feeding, and do not plan to become pregnant during the trial.&#xD;
             In addition, they must either have had a hysterectomy or tubal ligation at least 6&#xD;
             months before signing informed consent, be post-menopausal for 1 year, or practicing&#xD;
             an acceptable method of birth control. An acceptable method of birth control may be&#xD;
             oral, injectable or implantable hormonal contraceptives, intrauterine device,&#xD;
             diaphragm plus spermicide, or female condom plus spermicide. Abstinence, partner's use&#xD;
             of condoms, and partner's vasectomy are NOT acceptable methods of contraception&#xD;
&#xD;
          -  BMI 25 - 45 kg/M sq, inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects are excluded from participation in the study if any of the following criteria&#xD;
        apply:&#xD;
&#xD;
          -  Type 1 diabetes mellitus or history of diabetic ketoacidosis&#xD;
&#xD;
          -  Treatment with lipid or blood pressure lowering therapy that has not been stable for&#xD;
             three months before randomization&#xD;
&#xD;
          -  Treatment with WelChol, cholestyramine or colestipol for hyperlipidemia within the&#xD;
             last 3 months&#xD;
&#xD;
          -  Treatment with thiazolidinediones&#xD;
&#xD;
          -  History of dysphagia, swallowing disorders, or intestinal motility disorder&#xD;
&#xD;
          -  Serum triglyceride &gt;500 mg/dL at Visit 1&#xD;
&#xD;
          -  Serum LDL-C &lt;60 mg/dL at Visit 1&#xD;
&#xD;
          -  Any condition or therapy which, in the opinion of the investigator, poses a risk to&#xD;
             the subject or makes participation not in the subject's best interest&#xD;
&#xD;
          -  Use of any investigational drug within 30 days before randomization&#xD;
&#xD;
          -  Chronic treatment with oral corticosteroids&#xD;
&#xD;
          -  History of hyperthyroidism and/or treatment with thyroid hormone/ levothyroxine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Director Clinical Development</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes and Glandular Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <study_first_submitted>August 3, 2006</study_first_submitted>
  <study_first_submitted_qc>August 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2006</study_first_posted>
  <last_update_submitted>June 24, 2008</last_update_submitted>
  <last_update_submitted_qc>June 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Vice President Clinical Development</name_title>
    <organization>Daiichi Sankyo</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colesevelam Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

